



CST Bulletin - December, 2024

Update: BC Cancer Systemic Therapy Updates for December 2024

AFFECTED APPLICATION(S)	PowerChart	
AFFECTED AREA(S)	BC Cancer Sites/VCH Oncology Sites (Oncologists, Oncology Pharmacy, and Oncology Nursing Staff)	
NET NEW, OR UPDATE TO EXISTING BUILD	Update to Existing Build	


What has Changed?

Any changes released that affect Oncology Regimens and PowerPlans/Cycles for the **BC Cancer Systemic Therapy (ST) Program** will be communicated monthly via Special Bulletin.

These notification changes are important for Nursing staff, Pharmacy, and Providers to be aware of for their patient's care.

For Providers:

- For PowerPlans that are versioned: If your patient has already started on a Regimen, when you order the next cycle PowerPlan, a pop-up window will appear to indicate a new version is required.
 - Click Yes to accept the new version.
 - o **Do not** use the Copy Forward functionality to ensure that the updates apply.



IMPORTANT: Any change from the standard treatment regimen (dose modification, addition of
pre-med, etc.) in the previous cycle will need to be manually added to the cycle that is being
ordered with the new version (see additional documentation regarding versioning)

Please see this month's changes below.






Protocol: SATEMBEV

Cycles/PowerPlans: ONCP SA SATEMBEV Cycle 1, ONCP SA SATEMBEV Cycles 2+

Changes:

In the Prescriptions Phase:

• Removed CDS Note from Pre-Chemo metrics section: Creatinine Less Than or Equal to 2 x ULN within 24 hours (if ordered).



In the Labs Phase:

- Removed CDS Note: Prior to every odd numbered cycle.
- Moved Creatinine and Estimated EGFR order from "Prior to every odd numbered cycle" section to "If clinically indicated" section.



In the Scheduling Phase:

 Updated - Infusion Chemotherapy Visit Nurse and Chair Times in Scheduling Phase, Cycle 1





- Day 8: Nurse Time 60, Chair Time 135
- o Day 22: Nurse Time 60, Chair Time 60
- Updated Infusion Chemotherapy Visit Nurse and Chair Times in Scheduling Phase, Cycle 2+
 - o Day 8 and Day 22: Nurse Time 60, Chair Time 60

Versioning: Yes


Jira: CST-293035

Protocol: ONCP GI GIAAVCT


Cycles/PowerPlans: ONCP GI GIAAVCT

Changes:

• **Updated Order Comment** for **ondansetron** order to 'Do not give if patient given netupitant-palonosetron. Between 30 and 60 minutes prior to CARBOplatin. Day 1'.



- Added optional orders on Day 1:
 - Aprepitant 125mg (mutually exclusive with netupitant/palonosetron)
 - Netupitant-palonosetron 1 Cap
 - o Olanzapine (2.5mg, 5mg, 10mg options)
- Added yellow CDS note: 'Reminder to deselect ondansetron if giving netupitantpalonosetron.'



- **Update:** Infusion Chemotherapy Visit order for Day 1 Chair Time: 165 minutes, Nurse Time: 75 minutes.
- **Update:** Infusion Chemotherapy Visit order for Day 8 and 15 Chair Time: 135 minutes, Nurse Time: 75 minutes.






	△ Schedulable Orders		
E	⊽	📝 Infusion Chemotherapy Visit	
		Within 2 Weeks Chair Time: 165 minutes, Nurse Time: 75 minutes, ONCP GI GIAAVCT	
		Day 1	
F	⊽	📝 Infusion Chemotherapy Visit	
		Within 2 Weeks, Chair Time: 135 minutes, Nurse Time: 75 minute, ONCP GI GIAAVCT	
		Day 8	
F	⊽	🔭 Infusion Chemotherapy Visit	
		Within 2 Weeks, Chair Time: 135 minutes, Nurse Time: 75 minute, ONCP GI GIAAVCT	
		Day 15	
Versio	ning:	: Yes	
Jira: CST-293514			

Protocol: PUCAT

Cycles/PowerPlans: Treatment PowerPlans

Changes:

- Added Order Comment to ondansetron "Do not give if patient given netupitantpalonosetron."
- Added the following optional orders:
 - Aprepitant 125mg (mutually exclusive with netupitant/palonosetron)
 - Netupitant-palonosetron 1 Cap
 - o Olanzapine (2.5mg, 5mg, 10mg options)
- Added yellow CDS note: 'Reminder to deselect ondansetron if giving netupitantpalonosetron.'



Versioning: Yes





Jira: CST-293960


Protocol: CNCARV

Cycles/PowerPlans: ONCP CN CARV

Changes:

Added preselected: ondansetron 8mg.


- Added optional orders:
 - Aprepitant 125mg (mutually exclusive with netupitant/palonosetron)
 - Netupitant-palonosetron 1 Cap
 - Olanzapine (2.5mg, 5mg, 10mg options)
- Added yellow CDS note 'Reminder to deselect ondansetron if giving netupitantpalonosetron.'



Updated: Chair times:

Cycle 1: 165 minutes

Cycles 2+: 150 minutes



Versioning: Yes

Jira: CST-293208






Protocol: MY Protocols

Cycles/PowerPlans: List of affected PowerPlans below

Changes:

For Pretreatment PowerPlans:

Updated yellow note: "If HBsAg or HBcoreAb positive, start prophylaxis as per SCHBV."



List of affected PowerPlans:

- o ONCP MY MYBLDF Female of Childbearing Potential (FCBP) Pretreatment Plan
- ONCP MY MYBLDF Non Childbearing Potential (NCBP) Pretreatment Plan
- ONCP MY MYBLDPRE Female of Childbearing Potential (FCBP) Pretreatment Plan
- ONCP MY MYBLDPRE Non Childbearing Potential (NCBP) Pretreatment Plan
- ONCP MY MYBORMTN Pretreatment Plan
- ONCP MY MYBORPRE Pretreatment Plan
- o ONCP MY MYBORREL Pretreatment Plan
- o ONCP MY MYBSD Pretreatment Plan
- ONCP MY MYCARDEX Pretreatment Plan
- o ONCP MY MYCARLD Female of Childbearing Potential (FCBP) Pretreatment Plan
- ONCP MY MYCARLD Non Childbearing Potential (NCBP) Pretreatment Plan
- ONCP MY MYDARBD Pretreatment Plan
- ONCP MY MYDARCBDF Pretreatment Plan





- o ONCP MY MYDARLD Female of Childbearing Potential (FCBP) Pretreatment Plan
- ONCP MY MYDARLD Non Childbearing Potential (NCBP) Pretreatment Plan
- ONCP MY MYDARLDF Female of Childbearing Potential (FCBP) Pretreatment Plan
- o ONCP MY MYDARLDF Non Childbearing Potential (NCBP) Pretreatment Plan
- o ONCP MY MYLDREL Female of Childbearing Potential (FCBP) Pretreatment Plan
- o ONCP MY MYLDREL Non Childbearing Potential (NCBP) Pretreatment Plan
- ONCP MY MYLENMTN Female of Childbearing Potential (FCBP) Pretreatment Plan
- ONCP MY MYLENMTN Non Childbearing Potential (NCBP) Pretreatment Plan
- ONCP MY MYMP (PO) Pretreatment Plan
- ONCP MY MYMPBOR Pretreatment Plan
- ONCP MY UMYISACARD Pretreatment Plan
- ONCP MY UMYISAPOMD Female of Childbearing Potential (FCBP) Pretreatment Plan
- o ONCP MY UMYISAPOMD Non Childbearing Potential (NCBP) Pretreatment Plan
- o ONCP MY UMYLDF Female of Childbearing Potential (FCBP) Pretreatment Plan
- ONCP MY UMYLDF Non Childbearing Potential (NCBP) Pretreatment Plan
- ONCP MY UMYPOMDEX Female of Childbearing Potential (FCBP) Pretreatment Plan
- ONCP MY UMYPOMDEX Non Childbearing Potential (NCBP) Pretreatment Plan

For Treatment PowerPlans:

Added: Clinically indicated Hepatitis B Viral Load.

		MYBLDF Female of Childbearing Potential (FCBP) Cycle 1 - Cy				
		Component	Day 8	Day 15	Day 22	Day 29
æ	87		Future Pending	Future Pending	Future Pending	Future Pending
	Ι,		*Est. 04-Dec-2024 08:	*Est. 11-Dec-2024 08:	*Est. 18-Dec-2024 08:	*Est. 25-Dec-2024 08:
			Actions ▼	Actions ▼	Actions ▼	Actions ▼
		﴿ ♦ If clinically indicated:				
		CBC and Differential				
		Blood, once, Order for future visit				
		Creatinine and Estimated GFR				
		Blood, once, Order for future visit				
		Sodium and Potassium Panel (Electrolytes Panel Outpat				
		Blood, once, Order for future visit				
	P	Bilirubin Total				
		Blood, once, Order for future visit				
		Alanine Aminotransferase				
		Blood, once, Order for future visit				
		Alkaline Phosphatase				
		Blood, once, Order for future visit				
		🛱 Glucose Random				
		Blood, once, Order for future visit				
		Calcium Level				
		Blood, once, Order for future visit				
		Albumin Level				
		Blood, once, Order for future visit				
		Protein Electrophoresis Urine				
		Urine, once, Order for future visit				
	g.	mmunoglobulin Panel (IgA, IgG, IgM)				
		Blood, once, Order for future visit				
		Beta 2 Microglobulin				
	_	Blood, once. Order for future visit				
	P	Hepatitis B Viral Load (Rx monitoring)				
		Blood, once, Order for future visit				





• List of Affected PowerPlans:

- ONCP MY MYBLDF Female of Childbearing Potential (FCBP) Cycle 1
- ONCP MY MYBLDF Female of Childbearing Potential (FCBP) Cycles 2 to 8
- o ONCP MY MYBLDF Female of Childbearing Potential (FCBP) Cycles 9+
- ONCP MY MYBLDF Non Childbearing Potential (NCBP) Cycles 1 to 8
- ONCP MY MYBLDF Non Childbearing Potential (NCBP) Cycles 9+
- ONCP MY MYBLDPRE Female of Childbearing Potential (FCBP) Cycle 1
- ONCP MY MYBLDPRE Female of Childbearing Potential (FCBP) Cycles 2+
- ONCP MY MYBLDPRE Non Childbearing Potential (NCBP)
- ONCP MY MYBORMTN
- ONCP MY MYBORPRE Twice Weekly
- o ONCP MY MYBORPRE Weekly
- ONCP MY MYBORREL Twice Weekly
- ONCP MY MYBORREL Weekly
- ONCP MY MYBSD Cycle 1
- o ONCP MY MYBSD Cycles 2+
- ONCP MY MYCARDEX Cycle 1
- ONCP MY MYCARDEX Cycles 2+
- ONCP MY MYCARDEX Cyclophosphamide Option Cycle 1
- ONCP MY MYCARDEX Cyclophosphamide Option Cycles 2+
- ONCP MY MYCARLD Female of Childbearing Potential (FCBP) Cycle 1
- ONCP MY MYCARLD Female of Childbearing Potential (FCBP) Cycles 19+ (PO)
- ONCP MY MYCARLD Female of Childbearing Potential (FCBP) Cycles 2 to 18
- ONCP MY MYCARLD Non Childbearing Potential (NCBP) Cycle 1
- ONCP MY MYCARLD Non Childbearing Potential (NCBP) Cycles 19+ (PO)
- ONCP MY MYCARLD Non Childbearing Potential (NCBP) Cycles 2 to 18
- ONCP MY MYDARBD Cycle 2
- ONCP MY MYDARBD Cycles 3 and 4
- ONCP MY MYDARBD Cycles 5 to 8
- ONCP MY MYDARBD Cycles 9+
- ONCP MY MYDARBD First Dose IV Cycle 1
- ONCP MY MYDARBD First Dose IV Split Dosing Cycle 1
- ONCP MY MYDARBD First Dose Subcutaneous Cycle 1





- ONCP MY MYDARCBDF Cycle 2
- ONCP MY MYDARCBDF Cycles 10+
- ONCP MY MYDARCBDF Cycles 3 to 6
- ONCP MY MYDARCBDF Cycles 7 to 9
- ONCP MY MYDARCBDF First Dose IV Cycle 1
- ONCP MY MYDARCBDF First Dose IV Split Dosing Cycle 1
- ONCP MY MYDARCBDF First Dose Subcutaneous Cycle 1
- ONCP MY MYDARLD Female of Childbearing Potential (FCBP) Cycle 2
- ONCP MY MYDARLD Female of Childbearing Potential (FCBP) Cycles 3 to 6
- ONCP MY MYDARLD Female of Childbearing Potential (FCBP) Cycles 7+
- ONCP MY MYDARLD Female of Childbearing Potential (FCBP) First Dose IV Cycle 1
- ONCP MY MYDARLD Female of Childbearing Potential (FCBP) First Dose Subcutaneous Cycle 1
- ONCP MY MYDARLD Female of Childbearing Potential FCBP First Dose IV Split Dosing Cycle1
- ONCP MY MYDARLD Non Childbearing Potential (NCBP) Cycle 2
- o ONCP MY MYDARLD Non Childbearing Potential (NCBP) Cycles 3 to 6
- ONCP MY MYDARLD Non Childbearing Potential (NCBP) Cycles 7+
- ONCP MY MYDARLD Non Childbearing Potential (NCBP) First Dose IV Cycle 1
- ONCP MY MYDARLD Non Childbearing Potential (NCBP) First Dose IV Split Dosing Cycle 1
- ONCP MY MYDARLD Non Childbearing Potential (NCBP) First Dose Subcutaneous Cycle 1
- ONCP MY MYDARLDF Female of Childbearing Potential (FCBP) Cycle 2
- ONCP MY MYDARLDF Female of Childbearing Potential (FCBP) Cycles 3 to 6
- ONCP MY MYDARLDF Female of Childbearing Potential (FCBP) Cycles 7+
- ONCP MY MYDARLDF Female of Childbearing Potential (FCBP) First Dose IV Cycle 1
- ONCP MY MYDARLDF Female of Childbearing Potential (FCBP) First Dose Subcutaneous Cycle 1
- ONCP MY MYDARLDF Female of Childbearing Potential FCBP First Dose IV Split Dosing Cycle1
- ONCP MY MYDARLDF Non Childbearing Potential (NCBP) Cycle 2
- ONCP MY MYDARLDF Non Childbearing Potential (NCBP) Cycles 3 to 6
- ONCP MY MYDARLDF Non Childbearing Potential (NCBP) Cycles 7+
- ONCP MY MYDARLDF Non Childbearing Potential (NCBP) First Dose IV Cycle 1





- ONCP MY MYDARLDF Non Childbearing Potential (NCBP) First Dose IV Split Dosing Cycle 1
- ONCP MY MYDARLDF Non Childbearing Potential (NCBP) First Dose Subcutaneous Cycle 1
- o ONCP MY MYLDREL Female of Childbearing Potential (FCBP) Cycle 1
- ONCP MY MYLDREL Female of Childbearing Potential (FCBP) Cycles 2+
- ONCP MY MYLDREL Non Childbearing Potential (NCBP)
- ONCP MY MYLENMTN Female of Childbearing Potential (FCBP) Cycle 1
- ONCP MY MYLENMTN Female of Childbearing Potential (FCBP) Cycles 2+
- ONCP MY MYLENMTN Non Childbearing Potential (NCBP)
- o ONCP MY MYMP (PO)
- o ONCP MY MYMPBOR Cycles 1 and 2
- ONCP MY MYMPBOR Cycles 3+
- ONCP MY UMYISACARD Cycle 1
- ONCP MY UMYISACARD Cycles 2+
- o ONCP MY UMYISAPOMD Female of Childbearing Potential (FCBP) Cycle 1
- o ONCP MY UMYISAPOMD Female of Childbearing Potential (FCBP) Cycles 2+
- ONCP MY UMYISAPOMD Non Childbearing Potential (NCBP) Cycle 1
- ONCP MY UMYISAPOMD Non Childbearing Potential (NCBP) Cycles 2+
- ONCP MY UMYLDF Female of Childbearing Potential (FCBP) Cycle 1
- ONCP MY UMYLDF Female of Childbearing Potential (FCBP) Cycles 2+
- ONCP MY UMYLDF Non Childbearing Potential (NCBP)
- ONCP MY UMYPOMDEX Female of Childbearing Potential (FCBP) Cycle 1
- ONCP MY UMYPOMDEX Female of Childbearing Potential (FCBP) Cycles 2+
- ONCP MY UMYPOMDEX Non Childbearing Potential (NCBP)

Versioning: Yes

Jira: CST-292853

Protocol: LYCARTOP, LYCTCLBV

Cycles/PowerPlans: All PowerPlans

Changes:

All Regimens/PowerPlans are now deactivated.

Versioning: No





Jira: CST-293199, CST-292687

Protocol: HLHETCSPA, LYACAL, LYALEM, LYALIT, LYASPMEDEX, LYBEND, LYCDA, LYCHLOR, LYCHOP, LYCHPBV, LYCLLBEND, LYCSPA, LYCVP, LYCVPPABO, LYCYCLO, LYDARCBDF, LYFACAL, LYFIBRU, LYFLU, LYGDP, LYGEMOXPEG, LYGVLD, LYHDMRTEM, LYHDMTXPRO, LYIBRU, LYIT, LYIVACR, LYMFBEX, LYMIBRU, LYNIV, LYPALL, LYPEM, LYPEM6, LYPRA, LYSILTUX, LYSMILE, LYVENOB, LYVIPDRT, ULYROMI

Cycles/PowerPlans: All Associated PowerPlans and Regimens

Changes:


For Pretreatment PowerPlans:

- Updated: Preselected orders for Hepatitis B Surface Antibody BCCDC, Hepatitis B Surface Antibody PHC, Hepatitis B Core Antibody Total BCCDC, Hepatitis B Core Antibody Total PHC, Hepatitis B Surface Antigen BCCDC and Hepatitis B Surface Antigen PHC.
- **Updated Yellow Clinical Decision Support Note:** Changed to 'If HBsAg or HBcoreAb positive, start prophylaxis as per SCHBV.'

✓	Ż	Hepatitis B Core Antibody Total BCCDC	Blood, once, Order for future visit
哮	2 💆	Hepatitis B Surface Antigen BCCDC	Blood, once, Order for future visit
哮	. 🕏	Hepatitis B Surface Antibody BCCDC	Blood, once, Order for future visit
	⟨9	If HBsAg or HBcoreAb positive, start prophylaxis as per SCHBV	

For Treatment PowerPlans:

• **Updated**: Optional HBV Viral Load and either preselected or optional Alanine Aminotransferase dependent on PPO/Protocol prior to each cycle.



Versioning: Yes

Jira: CST-293518





Net New Protocol: GIGAVPCOXT, GIGAVPFOXT

- ONC GI GIGAVPFOXT
- ONCP GI GIGAVPFOXT Cycle 1
- ONCP GI GIGAVPFOXT Cycles 2+
- ONCP GI GIGAVPFOXT Pretreatment Plan
- ONC GI GIGAVPFOXT
- ONCP GI GIGAVPFOXT Pretreatment Plan
- ONCP GI GIGAVPFOXT Cycle 1
- ONCP GI GIGAVPFOXT Cycle 2+

Jira: CST-287959, CST-287960

Jira Ticket #	CST-293960, CST-293518, CST-293514, CST-293208, CST-293199, CST-293035, CST-292853, CST-292687, CST-287960, CST-287959
How-to questions?	http://cstcernerhelp.healthcarebc.ca
Need further support?	CST Phone Support: 1-844-214-7444



